Article Contents
| Clin Exp Pediatr > Volume 69(7); 2026 |
|
Funding
This research was supported by the Ministry of Health & Welfare (RS-2025-02220492 to DKY), Republic of Korea. This research was supported by Research of the Korea National Institute of Health (NIH) research project (2025-ER0601-00#).
Acknowledgments
We would like to acknowledge all the health care workers involved in the diagnosis and treatment of respiratory distress syndrome in Korea. We would also like to thank the medical staff and organizers for their efforts in collecting medical records from the 75 hospitals participating in the Korean Neonatal Network.
| Characteristic | Total (n=10,394) |
BE (mEq/L) |
||||
|---|---|---|---|---|---|---|
| ≥0 (n=774) | -3 to 0 (n=2,724) | -6 to -3 (n=3,609) | -9 to -6 (n=2,012) | <-9 (n=1,275) | ||
| Sex | ||||||
| Female | 5,190 (49.93) | 394 (50.90) | 1,416 (51.98) | 1,812 (50.21) | 941 (46.77) | 627 (49.18) |
| Male | 5,204 (50.07) | 380 (49.10) | 1,308 (48.02) | 1,797 (49.79) | 1,071 (53.23) | 648 (50.82) |
| Birth year | ||||||
| 2013–2015 | 4,202 (40.43) | 319 (41.21) | 1,095 (40.20) | 1,425 (39.48) | 828 (41.15) | 535 (41.96) |
| 2016–2019 | 6,192 (59.57) | 455 (58.79) | 1,629 (59.80) | 2,184 (60.52) | 1,184 (58.85) | 740 (58.04) |
| Prenatal steroids use | ||||||
| No | 1,744 (16.78) | 85 (10.98) | 435 (15.97) | 592 (16.40) | 336 (16.70) | 296 (23.22) |
| Yes | 8,650 (83.22) | 689 (89.02) | 2,289 (84.03) | 3,017 (83.60) | 1,676 (83.30) | 979 (76.78) |
| Gestational agea) (wk) | ||||||
| 22–27 | 3,549 (34.14) | 228 (29.46) | 826 (30.32) | 1,125 (31.17) | 782 (38.87) | 588 (46.12) |
| 28–33 | 6,178 (59.44) | 512 (66.15) | 1,710 (62.78) | 2,221 (61.54) | 1,113 (55.32) | 622 (48.78) |
| ≥34 | 667 (6.42) | 34 (4.39) | 188 (6.9) | 263 (7.29) | 117 (5.82) | 65 (5.1) |
| Apgar score, 1 min | ||||||
| 0–3 | 2,707 (26.04) | 139 (17.96) | 500 (18.36) | 816 (22.61) | 533 (27.49) | 699 (54.82) |
| 4–5 | 3,360 (32.33) | 268 (34.63) | 891 (32.71) | 1,154 (31.98) | 710 (35.29) | 337 (26.43) |
| ≥6 | 4,327 (41.63) | 367 (47.42) | 1,333 (48.94) | 1,639 (45.41) | 749 (37.23) | 239 (18.75) |
| Apgar score, 5 min | ||||||
| 0–3 | 520 (5.00) | 16 (2.07) | 70 (2.57) | 115 (3.19) | 92 (4.57) | 227 (17.80) |
| 4–5 | 1,125 (10.82) | 54 (6.98) | 219 (8.04) | 324 (8.98) | 255 (12.67) | 273 (21.41) |
| ≥6 | 8,749 (84.17) | 704 (90.96) | 2,435 (89.39) | 3,170 (87.84) | 1,665 (82.75) | 775 (60.78) |
| Birth weight (g) | ||||||
| <500 | 167 (1.61) | 8 (1.03) | 23 (0.84) | 42 (1.16) | 42 (2.09) | 52 (4.08) |
| 500–1,000 | 3,427 (32.97) | 225 (29.07) | 822 (30.18) | 1,074 (29.76) | 742 (36.88) | 564 (44.24) |
| ≥1,000 | 6,800 (65.42) | 541 (69.90) | 1,879 (69.08) | 2,493 (69.08) | 1,228 (61.03) | 659 (51.69) |
| Maternal age (yr) | 33.28±4.22 | 33.10±4.16 | 33.12±4.12 | 33.32±4.25 | 33.44±4.26 | 33.35±4.34 |
| Temperature at birth (℃) | ||||||
| <35.5 | 992 (9.54) | 46 (5.94) | 201 (7.38) | 309 (8.56) | 231 (11.48) | 205 (16.08) |
| 35.5–37.5 | 9,289 (89.37) | 716 (89.37) | 2,490 (91.41) | 3,264 (90.44) | 1,762 (87.57) | 1,057 (82.90) |
| ≥37.5 | 113 (1.09) | 12 (0.12) | 33 (0.32) | 36 (0.35) | 19 (0.18) | 13 (0.13) |
| Respiratory outcomes | BE (mEq/L) | Events/population (%) | Crude OR | Adjusted ORa) |
|---|---|---|---|---|
| Air leak syndrome | ≥0 | 26/774 (3.36) | 1.0 (reference) | 1.0 (reference) |
| -3 to 0 | 83/2,724 (3.05) | 0.904 (0.578–1.415) | 0.890 (0.566–1.401) | |
| -6 to -3 | 145/3,609 (4.02) | 1.204 (0.787–1.842) | 1.182 (0.770–1.816) | |
| -9 to -6 | 108/2,012 (5.37) | 1.632 (1.055–2.525)* | 1.568 (1.007–2.442)* | |
| <-9 | 89/1,275 (6.98) | 2.159 (1.381–3.374)* | 2.071 (1.305–3.285)* | |
| Massive pulmonary hemorrhage | ≥0 | 28/774 (3.62) | 1.0 (reference) | 1.0 (reference) |
| -3 to 0 | 91/2,724 (3.34) | 0.921 (0.598–1.417) | 0.928 (0.601–1.433) | |
| -6 to -3 | 149/3,609 (4.13) | 1.147 (0.760–1.731) | 1.160 (0.766–1.757) | |
| -9 to -6 | 113/2,012 (5.62) | 1.585 (1.039–2.419)* | 1.494 (0.977–2.286) | |
| <-9 | 105/1,275 (8.24) | 2.391 (1.560–3.664)* | 2.317 (1.502–3.575)* | |
| Pulmonary hypertension | ≥0 | 53/774 (6.85) | 1.0 (reference) | 1.0 (reference) |
| -3 to 0 | 140/2,724 (5.14) | 0.737 (0.531–1.022) | 0.754 (0.545–1.045) | |
| -6 to -3 | 249/3,609 (6.90) | 1.008 (0.741–1.371) | 1.020 (0.751–1.386) | |
| -9 to -6 | 196/2,012 (9.74) | 1.468 (1.071–2.013)* | 1.455 (1.062–1.993)* | |
| <-9 | 176/1,275 (13.80) | 2.179 (1.580–3.004)* | 2.296 (1.667–3.161)* | |
| Neonatal respiratory distress syndrome | ≥0 | 554/775 (71.58) | 1.0 (reference) | 1.0 (reference) |
| -3 to 0 | 1,943/2,724 (71.33) | 0.988 (0.828–1.179) | 1.007 (0.842–1.204) | |
| -6 to -3 | 2,611/3,609 (72.35) | 1.039 (0.875–1.235) | 1.039 (0.875–1.235) | |
| -9 to -6 | 1,565/2,012 (77.78) | 1.390 (1.152–1.678)* | 1.420 (1.174–1.718)* | |
| <-9 | 1,074/1,275 (84.24) | 2.122 (1.708–2.636)* | 2.219 (1.778–2.769)* | |
| Bronchopulmonary dysplasia (severe) | ≥ 0 | 412/774 (53.23) | 1.0 (reference) | 1.0 (reference) |
| -3 to 0 | 1,486/2,724 (54.55) | 1.055 (0.899–1.238) | 1.075 (0.915–1.263) | |
| -6 to -3 | 1,981/3,609 (54.89) | 1.069 (0.915–1.249) | 1.086 (0.928–1.270) | |
| -9 to -6 | 1,268/2,012 (63.02) | 1.497 (1.266–1.771)* | 1.495 (1.263–1.771)* | |
| <-9 | 911/1,275 (71.45) | 2.199 (1.825–2.649)* | 2.262 (1.871–2.736)* | |
| Bronchopulmonary dysplasia (mild or moderate) | ≥0 | 182/774 (23.51) | 1.0 (reference) | 1.0 (reference) |
| -3 to 0 | 709/2,724 (26.03) | 1.145 (0.949–1.380) | 1.169 (0.968–1.411) | |
| -6 to -3 | 907/3,609 (25.13) | 1.092 (0.910–1.310) | 1.106 (0.920–1.329) | |
| -9 to -6 | 557/2,012 (27.68) | 1.245 (1.027–1.510)* | 1.270 (1.046–1.544)* | |
| <-9 | 401/1,275 (31.45) | 1.492 (1.217–1.830)* | 1.496 (1.217–1.839)* |
a) This model was adjusted for sex, birth year (2013–2015 and 2016–2019), prenatal steroids, gestational age (22–27 weeks, 28–33 weeks, and ≥34 weeks), birth weight (<500 g, 500–1,000 g, and ≥1,000 g), maternal age (continuous variable), and temperature at birth (<35.5°C, 35.5°C–37.5°C, and ≥37.5°C).
| Outcomes | BE (mEq/L) | Events/population (%) | Crude OR (95% CI) | Adjusted ORa) (95% CI) |
|---|---|---|---|---|
| Neurological morbidities | ≥0 | 261/774 (33.72) | 1.0 (reference) | 1.0 (reference) |
| -3 to 0 | 1,048/2,724 (38.47) | 1.229 (1.039–1.454)* | 1.250 (1.056–1.479)* | |
| -6 to -3 | 1,490/3,609 (41.29) | 1.382 (1.174–1.627)* | 1.404 (1.192–1.654)* | |
| -9 to -6 | 940/2,012 (46.72) | 1.723 (1.450–2.049)* | 1.729 (1.453–2.058)* | |
| <-9 | 740/1,275 (58.04) | 2.718 (2.257–3.274)* | 2.797 (2.314–3.380)* | |
| Infection-related outcomes | ≥0 | 121/774 (15.63) | 1.0 (reference) | 1.0 (reference) |
| -3 to 0 | 471/2,724 (17.29) | 1.128 (0.907–1.403) | 1.150 (0.925–1.430) | |
| -6 to -3 | 658/3,609 (18.23) | 1.203 (0.974–1.487) | 1.223 (0.991–1.511) | |
| -9 to -6 | 438/2,012 (21.77) | 1.501 (1.204–1.873)* | 1.534 (1.230–1.913)* | |
| <-9 | 347/1,275 (27.22) | 2.018 (1.603–2.540)* | 2.082 (1.653–2.623)* | |
| Gastrointestinal outcomes | ≥0 | 48/774 (6.20) | 1.0 (reference) | 1.0 (reference) |
| -3 to 0 | 157/2,724 (5.76) | 0.925 (0.663–1.291) | 0.952 (0.681–1.330) | |
| -6 to -3 | 244/3,609 (6.76) | 1.097 (0.797–1.510) | 1.118 (0.812–1.539) | |
| -9 to -6 | 181/2,012 (9.00) | 1.495 (1.075–2.079)* | 1.485 (1.068–2.063)* | |
| <-9 | 145/1,275 (11.37) | 1.941 (1.382–2.725)* | 1.979 (1.408–2.783)* | |
| Mortality | ≥0 | 89/774 (11.50) | 1.0 (reference) | 1.0 (reference) |
| -3 to 0 | 258/2,724 (9.47) | 0.805 (0.624–1.040) | 0.811 (0.628–1.047) | |
| -6 to -3 | 414/3,609 (11.47) | 0.997 (0.782–1.272) | 1.009 (0.791–1.288) | |
| -9 to -6 | 354/2,012 (17.59) | 1.643 (1.281–2.108)* | 1.594 (1.242–2.046)* | |
| <-9 | 327/1,275 (25.65) | 2.655 (2.059–3.423)* | 2.683 (2.076–3.466)* |
a) This model was adjusted for sex, birth year (2013–2015 and 2016–2019), prenatal steroids, gestational age (22–27 weeks, 28–33 weeks, and ≥34 weeks), birth weight (<500 g, 500–1,000 g, and ≥1,000 g), maternal age (continuous variable), and temperature at birth (<35.5°C, 35.5°C–37.5°C, and ≥37.5°C).